Atherosclerosis
Volume 204, Issue 2 , Pages 491-496 , June 2009

Patterns of statin prescription in acute myocardial infarction: The French registry of Acute ST-elevation or non-ST-elevation Myocardial Infarction (FAST-MI)

  • Jean Ferrières

      Affiliations

    • Cardiology department, CHU Rangueil, Toulouse, France
    • Corresponding Author InformationCorresponding author. Service de cardiologie B, CHU Rangueil, TSA 50032, 31059 Toulouse Cedex 9, France. Tel.: +33 5 61 52 18 70; fax: +33 561 32 33 35.
  • ,
  • Vincent Bataille

      Affiliations

    • INSERM U 558, Département d’Epidémiologie, Faculté de Médecine, Toulouse, France
  • ,
  • Florence Leclercq

      Affiliations

    • Department of Cardiology, CHU Montpellier, Montpellier 34295, France
  • ,
  • Philippe Geslin

      Affiliations

    • Department of Cardiology, University Hospital of Angers, Angers, France
  • ,
  • Jean-Bernard Ruidavets

      Affiliations

    • INSERM U 558, Département d’Epidémiologie, Faculté de Médecine, Toulouse, France
  • ,
  • Gilles Grollier

      Affiliations

    • Thoracic and Cardiovascular Surgery Department, University Hospital of Caen, Caen, France
  • ,
  • Paul Bernard

      Affiliations

    • Clinique du Pont de Chaume, Montauban, France
  • ,
  • Jean-Pierre Cambou

      Affiliations

    • Société Française de Cardiologie, Paris, France
  • ,
  • Tabassome Simon

      Affiliations

    • Department of Pharmacology, APHP-Saint Antoine hospital, Paris, France
  • ,
  • Nicolas Danchin

      Affiliations

    • Cardiology department, Hôpital Européen Georges Pompidou, Paris, France
    • For the FAST-MI Investigators.

Received 18 August 2008 ,Revised 15 September 2008 ,Accepted 21 September 2008.

References 

  1. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J. 2007;28:2375–2414
  2. Kotseva K, Stagmo M, De Bacquer D, et al. Treatment potential for cholesterol management in patients with coronary heart disease in 15 European countries: findings from the EUROASPIRE II survey. Atherosclerosis. 2008;197:710–717
  3. Penning-van Beest FJ, Termorshuizen F, Goettsch WG, et al. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J. 2007;28:154–159
  4. Acevedo M, Sprecher DL, Lauer MS, et al. Routine statin treatment after acute coronary syndromes?. Am Heart J. 2002;143:940–942
  5. Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA. 2001;285:430–436
  6. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischaemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711–1718
  7. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004;292:1307–1316
  8. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–1504
  9. Newby LK, Kristinsson A, Bhapkar MV, et al. Early statin initiation and outcomes in patients with acute coronary syndromes. JAMA. 2002;287:3087–3095
  10. Fonarow GC, Gawlinski A, Moughrabi S, et al. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol. 2001;87:819–822
  11. Fonarow GC, Ballantyne CM. In-hospital initiation of lipid-lowering therapy for patients with coronary heart disease: the time is now. Circulation. 2001;103:2768–2770
  12. Muhlestein JB, Horne BD, Bair TL, et al. Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. Am J Cardiol. 2001;87:257–261
  13. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  14. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–1435
  15. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437–2445
  16. Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48:438–445
  17. Hulten E, Jackson JL, Douglas K, et al. The effect of early, intensive statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trials. Arch Intern Med. 2006;166:1814–1821
  18. Afilalo J, Majdan AA, Eisenberg MJ, et al. Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. Heart. 2007;93:914–921
  19. Danchin N, Coste P, Ferrières J, et al. Comparison of thrombolysis followed by broad use of percutaneous coronary intervention with primary percutaneous coronary intervention for ST-segment-elevation acute myocardial infarction: data from the french registry on acute ST-elevation myocardial infarction (FAST-MI). Circulation. 2008;118:268–276
  20. Heart Protection Study Collaborative Group.. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22
  21. Spencer FA, Goldberg RJ, Gore JM, et al. Comparison of utilization of statin therapy at hospital discharge and six-month outcomes in patients with an acute coronary syndrome and serum low-density lipoprotein>or =100mg/dl versus <100mg/dl. Am J Cardiol. 2007;100:913–918
  22. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–1630
  23. Ito H, Ouchi Y, Ohashi Y, et al. A comparison of low versus standard dose pravastatin therapy for the prevention of cardiovascular events in the elderly: the pravastatin anti-atherosclerosis trial in the elderly (PATE). J Atheroscler Thromb. 2001;8:33–44
  24. Miida T, Otsuka H, Tsuchiya A, et al. Plasma lipoprotein profiles change significantly during cardiac catheterization. Clin Chem. 1998;44:517–521
  25. EUROASPIRE Study Group. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J. 1997;18:1569–1582
  26. Pitt B, Loscalzo J, Ycas J, et al. Lipid levels after acute coronary syndromes. J Am Coll Cardiol. 2008;51:1440–1445
  27. Setoguchi S, Glynn RJ, Avorn J, et al. Improvements in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge: a 10-year trend analysis. J Am Coll Cardiol. 2008;51:1247–1254
  28. Fox KA, Steg PG, Eagle KA, et al. Decline in rates of death and heart failure in acute coronary syndromes, 1999–2006. JAMA. 2007;297:1892–1900
  29. Lindgren P, Graff J, Olsson AG, et al. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin. Eur Heart J. 2007;28:1448–1453
  30. Nichols GA, Koro CE. Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients. Clin Ther. 2007;29:1761–1770
  31. Harper CR, Jacobson TA. Managing dyslipidaemia in chronic kidney disease. J Am Coll Cardiol. 2008;51:2375–2384

PII: S0021-9150(08)00693-X

doi: 10.1016/j.atherosclerosis.2008.09.031

Atherosclerosis
Volume 204, Issue 2 , Pages 491-496 , June 2009